Home > Insider Trading > Filing (0000899243-20-009016)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	C/O Longitude Capital Partners Ii, Llc 2740 Sand Hill Road, Second Floor Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2020-03-17	100,000	$11.40	6,113,134	No	4	P	Indirect	By: LVP2
Common Stock, $0.0001 Par Value	Acquisiton	2020-03-17	8,787	$11.50	54,348	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2020-03-18	16,213	$11.06	70,561	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By: LVP2
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $11.35 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting, investment and dispositive power with respect to such securities. The Reporting Person (a member of the Issuer's board of directors) and Juliet Tammenoms Bakker are the managing members of LCP II. Each of LCP II, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $10.66 to $11.50 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.